Renoprotective Effect of the L/N-Type Calcium Channel Antagonist Cilnidipine on Puromycin Aminonucleoside-Induced Nephrosis in Rats

Abstract

The renoprotective effect of cilnidipine ((±)-2-methoxyethyl 3-phenyl-2(E)-pro-penyl 1,4-dihydro-2,6-dimethyl-4-(3-ni-trophenyl)-3,5-pyridinedicarboxylate, CAS 132203-70-4), a L/N-type calcium channel antagonist, on puromycin aminonucleoside (PAN)-induced nephrosis was investigated in rats.

In the Experiment I, rats were given an intravenous injection of PAN (70 mg/kg). Cilnidipine (3 mg/kg/day) and enalapril (CAS 75847-73-3, 5mg/kg/day) were administered orally from 6 days after treatment with PAN (day 6) to day 26, and urinary analysis was performed on days 9, 15, 20 and 27. In the Experiment II, nephrosis was also induced by intravenous injection of PAN (70 or 100 mg/kg) in rats which were treated with cilnidipine and enalapril from days 6 to 10. Systolic blood pressure was measured on day 7 and urinary analysis was performed on day 10. On day 11, serum was collected and the kidneys were removed for immunofluorescence staining for nephrin and podocin proteins.

In PAN-treated rats, the daily urinary protein excretion was dramatically elevated on day 5, reached a peak on day 9 and gradually returned to a normal level from days 15 to 27. Cilnidipine (3 mg/kg/day) significantly suppressed the increase in proteinuria on day 9 and also improved the decrease in creatinine clearance without evident effect on the blood pressure. Furthermore, the elevations in serum total cholesterol and triglyceride tended to be suppressed by cilnidipine. The expression of nephrin and podocin proteins in PAN-treated rats showed the granular pattern in the glomeruli, while the intensity of staining seemed to be dependent on the urinary protein excretion level in the cilnidipinetreated rats.

The results obtained in this study suggest a renoprotective effect of cilnidipine in PAN-induced nephrosis in rats.

Key words

CAS 132203-70-4 - Calcium antagonist, L/N-type - Cilnidipine, renoprotective effect - Nephrosis, puromycin aminonucleoside-induced

• Literature

• 1 Fujii S, Kameyama K, Hosono M, Hayashi Y, Kitamura K. Effect of cilnidipine, a novel dihydropyridine Ca⁺⁺-channel antagonist, on N-type Ca⁺⁺ channel in rat dorsal root ganglion neurons. J Pharmacol Exp Ther. 1997; 280: 1184-91
• 2 Hirning LD, Fox AP, McCleskey EW, Olivera BM, Thayer SA, Miller RJ et al Dominant role of N-type Ca²⁺ channels in evoked release of norepinephrine from sympathetic neurons. Science. 1988; 239: 57-61
• 3 Hayashi K, Wakino S, Sugano N, Ozawa Y, Homma K, Saruta T. Ca²⁺ channel subtypes and pharmacology in the kidney. Circ Res. 2007; 100: 342-53
• 4 Hosono M, Hiruma T, Watanabe K, Hayashi Y, Ohnishi H, Takata Y et al Inhibitory effect of cilnidipine on pressor response to acute cold stress in spontaneously hypertensive rats. Jpn J Pharmacol. 1995; 69: 119-25
• 5 Hosono M, Fujii S, Hiruma T, Watanabe K, Hayashi Y, Ohnishi H et al Inhibitory effect of cilnidipine on vascular sympathetic neurotransmission and subsequent vasoconstriction in spontaneously hypertensive rats. Jpn J Pharmacol. 1995; 69: 127-34
• 6 Konda T, Enomoto A, Takahara A, Yamamoto H. Effects of L/N-type calcium channel antagonist, cilnidipine on progressive renal injuries in Dahl salt-sensitive rats. Biol Pharm Bull. 2006; 29: 933-7
• 7 Zhou X, Ono H, Ono Y, Frohlich ED. N- and L-type calcium channel antagonist improves glomerular dynamics, reverses severe nephrosclerosis, and inhibits apoptosis and proliferation in an l-NAME/SHR model. J Hypertens. 2002; 20: 993-1000
• 8 Kojima S, Shida M, Yokoyama H. Comparison between cilnidipine and amlodipine besilate with respect to proteinuria in hypertensive patients with renal diseases. Hypertens Res. 2004; 27: 379-85
• 9 Rose GW, Kanno Y, Ikebukuro H, Kaneko M, Kaneko K, Kanno T et al Cilnidipine is as effective as benazepril for control of blood pressure and proteinuria in hypertensive patients with benign nephrosclerosis. Hypertens Res. 2001; 24: 377-83
• 10 Frenk S, Antonowicz I, Craig JM, Metcoff J. Experimental nephrotic syndrome induced in rats by aminonucleoside; renal lesions and body electrolyte composition. Proc Soc Exp Biol Med. 1955; 89: 424-7
• 11 Diamond JR, Anderson S. Irreversible tubulointerstitial damage associated with chronic aminonucleoside nephrosis. Amelioration by angiotensin I converting enzyme inhibition. AmJ Pathol. 1990; 137: 1323-32
• 12 Luimula P, Sandström N, Novikov D, Holthofer H. Podocyte-associated molecules in puromycin aminonucleoside nephrosis of the rat. Lab Invest. 2002; 82: 713-8
• 13 Yayama K, Kawano M, Tujii H, Itoh N, Okamoto H. Dup 753 prevents the development of puromycin aminonucleoside-induced nephrosis. Eur J Pharmacol. 1993; 236: 337-8
• 14 Ebihara I, Nakamura T, Tomino Y, Koide H. Effect of a specific endothelin receptor A antagonist and an angiotensinconverting enzyme inhibitor on glomerular mRNA levels for extracellular matrix components, metalloproteinases (MMP) and a tissue inhibitor of MMP in aminonucleoside nephrosis. Nephrol Dial Transplant. 1997; 12: 1001-6
• 15 Kimura K, Tojo A, Hirata Y, Hayakawa H, Goto A, Omata M. Effects of a calcium antagonist and an angiotensin II receptor antagonist on rat renal arterioles. Blood Pres. Suppl. 1994; 3: 71-4
• 16 Bonnet F, Cooper ME, Kawachi H, Allen TJ, Boner G, Cao Z. Irbesartan normalises the deficiency in glomerular nephrin expression in a model of diabetes and hypertension. Diabetologia. 2001; 44: 874-7
• 17 Kawachi H, Koike H, Kurihara H, Sakai T, Shimizu F. Cloning of rat homologue of podocin: expression in proteinuric states and in developing glomeruli. J Am Soc Nephrol. 2003; 14: 46-56
• 18 Konda T, Takahara A, Maeda K, Dohmoto H, Yoshimoto R. Effects of a dual L/N-type Ca(2+) channel blocker cilnidipine on neurally mediated chronotropic response in anesthetized dogs. Eur J Pharmacol. 2001; 413: 117-20
• 19 Takahara A, Koganei H, Takeda T, Iwata S. Antisympathetic and hemodynamic property of a dual L/N-type Ca(2+) channel blocker cilnidipine in rats. Eur J Pharmacol. 2002; 434: 43-7
• 20 Hayashi K, Nagahama T, Oka K, Epstein M, Saruta T. Disparate effects of calcium antagonists on renal microcirculation. Hypertens Res. 1996; 19: 31-6
• 21 Kidney Disease Outcomes Quality Initiative(K/DOQI) K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis. 2004 43. S1-290
• 22 European Society of Hypertension-European Society of Cardiology Guidelines Committee 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension J Hypertens. 2003 21. 1011-53
• 23 Kawachi H, Kurihara H, Topham PS, Brown D, Shia MA, Orikasa M et al Slit diaphragm-reactive nephritogenic MAb 5-1-6 alters expression of ZO-1 in rat podocytes. Am J Physiol. 1997; 273: F984-93
• 24 Nakhoul F, Ramadan R, Khankin E, Yaccob A, Kositch Z, Lewin M et al Glomerular abundance of nephrin and podocin in experimental nephrotic syndrome: different effects of antiproteinuric therapies. Am J Physiol Renal Physiol. 2005; 289: F880-90
• 25 Luimula P, Ahola H, Wang SX, Solin ML, Aaltonen P, Tikkanen I et al Nephrin in experimental glomerular disease. Kidney Int. 2000; 58: 1461-8
• 26 Kawachi H, Koike H, Kurihara H, Yaoita E, Orikasa M, Shia MA et al Cloning of rat nephrin: expression in developing glomeruli and in proteinuric states. Kidney Int. 2000; 57: 1949-61
• 27 Chan MK, Varghese Z, Moorhead JF. Lipid abnormalities in uremia, dialysis, and transplantation. Kidney Int. 1981; 19: 625-37
• 28 Baxter JH. Hyperlipoproteinemia in nephrosis. Arch Intern Med. 1962; 109: 742-57
• 29 Gherardi E, Rota E, Calandra S, Genova R, Tamborino A. Relationship among the concentrations of serum lipoproteins and changes in their chemical composition in patients with untreated nephrotic syndrome. Eur J Clin Invest. 1977; 7: 563-70
• 30 Fujita T, Nakamura N, Kumasaka R, Shimada M, Murakami R, Osawa H et al Comparison of lipid and fatty acid metabolism between minimal change nephritic syndrome and membranous nephropathy. In Vivo. 2006; 20: 891-3
• 31 Shirakura S, Sano J, Karasawa A, Kubo K. Protective effect of benidipine against the development of glomerular sclerosis in experimental nephrotic syndrome. Jpn J Pharmacol. 1992; 59: 461-7
• 32 Kaysen GA, Hoye E, Jones H Jr, van Tol A, Joles JA. Effect of oncotic pressure on apolipoprotein A-I metabolism in the rat. AmJ Kidney Dis. 1995; 26: 178-86